Bioceres Crop Solutions Corp.BIOX

時価総額

PER

農業向けの生物学的生産性ソリューションの最大手。HB4耐性大豆・小麦や微小粒肥料、微生物製剤などの製品群を展開。2024年6月期売上高4.648億ドル、2022年7月の合併や2022年9月の10年独占販売契約を実施。南米、米国、欧州中心に45カ国以上で展開。

概要財務

サマリーテーブルに戻る

	2019年 6月30日	2020年 6月30日	2021年 6月30日	2022年 6月30日	2023年 6月30日	2024年 6月30日
Result for the year	-16,358,891	4	-3,820,622	-3,908,904	20	6
Income tax	7	2	14	18	-1,068,652	4
Financial results	41	33	28	26	35	35
Adjustments for depreciation expense	2	2	3	4	5	6
Amortization of intangible assets	2	2	2	4	11	12
Depreciation of leased assets	-	566,818	827,320	1	4	3
Transactional expenses	5	-	2	971,539	4	1
Adjustments for share-based payments	-	3	2	1	3	14
Share of profit or loss of joint ventures and associates	1	2	997,429	1	1	4
Loss of participation in joint ventures and associates	-	-	-	-	-133,079	-
Adjustments for provisions	-246,832	200,525	158,818	292,732	221,008	367,126
Allowance for impairment of trade debtors	686,985	1	560,931	2	1	753,428
Allowance for obsolescence	564,873	977,817	579,832	849,641	1	586,515
Initial recognition and changes in the fair value of biological assets	-	-716,741	-2,826,255	-6,388,030	-610,554	45,746
Changes in the net realizable value of agricultural products after harvest	-	-	-	-42,523	-4,351,433	-2,385,069
Gain on sale of equipment and intangible assets	91,762	297,289	733,042	-1,944,308	-74,593	-125,464
Trade receivables	41	-23,022,695	2	-24,971,064	-56,867,123	-46,681,153
Other receivables	6	-4,827,495	-8,330,278	-7,298,822	-11,475,717	-4,967,150
Income and minimum presumed income taxes	3	1	6	6	-16,154,083	5
Inventories and biological assets	-	-	35	55	11	-14,176,656
Trade and other payables	-33,699,077	8	-5,831,743	53	-4,501,398	14
Employee benefits and social security	931,656	-474,220	-693,125	3	1	-2,289,095
Deferred revenue and advances from customers	66,178	864,905	2	-373,584	13	-21,087,704
Income taxes paid	-1,705,481	-	-1,837,775	-7,059,177	-4,072,347	-853,299
Government grants	-23,019	-6,603	-2,821	-784	-	-
Interest collected	-	1	3	6	5	3
Inflation effects on working capital adjustments	-18,411,538	-13,663,552	-14,735,250	-35,846,973	376,597	321,103
Net cash flows generated / (used) by operating activities	30	11	-6,205,943	-17,515,374	3	42
Proceeds from sale of property, plant and equipment	317,953	51,151	309,810	2	137,357	336,726
Net cash received from business combination	-	-	355,804	-	4	37,508
Net loans granted to shareholders and other related parties	-	-	-	421,691	-	-
Proceeds from financial assets	-	-	-	-	1	888,140
Investment in financial assets	-	-	-	-	-	7
Purchase of property, plant and equipment	2	2	3	3	11	10
Capitalized development expenditures	682,530	1	4	5	11	12
Purchase of intangible assets	722,833	2	7	389,039	449,673	1
Net cash flows (used) /generated by investing activities	-3,260,852	-22,212,249	-8,310,118	3	-25,725,670	-28,728,255
Proceeds from borrowings	89	135	143	140	80	136
Repayment of borrowings and financed payments	111	101	126	124	17	113
Interest payments	-	-	-	-	18	25
Decrease in bank overdrafts and other short-term borrowings	-4,968,813	-2,331,974	-3,442,491	-32,838	-	-
Other financial payments	-854,731	2	-1,415,034	-180,538	-4,767,378	-2,746,945
Acquisition of non-controlling interest in subsidiaries	-	-	-	724,429	-	-
Purchase of own shares	-	30,906	4	-	3	734,388
Leased assets payments	-	433,947	728,964	1	4	5
Cash dividend distributed by subsidiary	-	-	-	-	452,129	174,800
Net cash flows (used) /generated by financing activities	-26,946,194	34	7	15	33	-10,055,867
Net increase in cash and cash equivalents	-512,233	23	-7,157,932	211,214	10	3
Inflation effects on cash and cash equivalents	2	-552,459	-5,584,156	-9,624,750	-101,767	-31,918
Effect of exchange rate changes on cash and equivalents	66,890	2	6	7	5	-6,556,470